Please type a plus sign (+) inside this box →	
---	--

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of

Complete if Known							
Application Number	10/734,573						
Filing Date	12-12-2003						
First Named Inventor	FRICK, et al.						
Group Art Unit	Not Yet Known						
Examiner Name	Not Yet Known						
Attomey Docket Number	DEAV2002/0087 - US - NP						

I	U.S. PATENT DOCUMENTS							
initials I No I Number		Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
/RI/		10/151,436		Bristol-Myers Squibb Company	05-20-2002			
		6221633		ERTL	04-24-2001			
		6221897		BARINGHAUS	04-24-2001			
\sqrt{N}		6245744		BARINGHAUS	06-12-2001			
V		6342512		KIRSCH	01-29-2002			
								
		<u> </u>						
		l						

				FOR	EIGN PATENT DOCUMENT	S				1
Examiner Cite Initials No.1		Office ³	Foreign Patent Oo Number	Cument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	V Pass	s, Columns, Lines, /here Relevant sages or Relevant igures Appear	Т6	
		Ţ	0 463 884		Adir et compagnio	12 27 1001	-No	translat	ic	h
		50	0 860 048		Tenebe Seiyaku Ge., Ltd.	07 01 1000	_No	transla	ti	Þ١
		DБ	10142734		CLOMBIK	03-27-2003	- No	o transl	at:	1
1		3	2000-00041			03-21-2000	- No	transla	Ei	Þ
/RI/		wo	00/40569		Alizyme Therapeutics Limited	07-13-2000				1
/RI/		wo	00/63208		Novo Nordisk A/S - Boehringer	10-26-2000				1
		wo	00/64876			11-02-2000				1
		WO	00/64888			11-02-2000			1	1
7/		wo	00/66585		Neurogen Corporation	11-09-2000				Ī
W		wo	00/71549		Knoll Aktiengesellschaft	11-30-2000			Т	Ī

\	Examiner Signature	/Roy Issac/ (04/30/2007)	Date Considered	04/30/2007
---	--------------------	--------------------------	--------------------	------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.



Please type a plus sign (+) inside this box →	PTO/SB/08A (10-96) Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE	+
	Patent and Trademark Onice, 0.5, DEPARTMENT OF COMMERCE	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	te for form 1449A/P	то		Complete if Known			
				Application Number	10/734,573		
INF	DRMA FIOI	N DIS	SCLOSURE	Filing Date	12-12-2003		
STA	TEMENT	BY A	PPLICANT	First Named Inventor	FRICK, et al.		
				Group Art Unit	Not Yet Known		
	(use as many sl	neets as	necessary)	Examiner Name	Not Yet Known		
Sheet	2	of	5	Attorney Docket Number	DEAV2002/0087 - US - NP		


	U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.1	U.S. Paten Number	t Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Pessages or Relevant Figures Appear		
					<u></u>			
								
	↓			······				
				· · · · · · · · · · · · · · · · · · ·				
								
		···						
					<u> </u>			
<u>.</u>								
]								

				FOR	EIGN PATENT DOCUMENT	S			ĺ
···	011-		Foreign Patent Document		Name of Patentee or	Date of Publication of	Pages, Columns, Lines,		ĺ
Examiner Cite Initials No.1	No.1	Office	3 Number ⁴	Kind Code ^s (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T6	
/RI/		wo	00/78312		Merck & Co., Inc.	12-28-2000			ĺ
/RI/		wo	01/09111		Eli Lilly and Company	02-08-2001			
		VVO	01/10147		Kissel Pharmaceutical Co., Ltd	03-08-2001	No translat	Eid	n
7RI/		wo	01/27128.		Bristol-Myers Squibb Company	04-19-2001			ĺ
		WO-	04/68668		Kissel Pharmaceuticals Co., Li	09-20-2001	No trans	Ιa	ti
		wo	01/74834		Bristol-Myers Squibb Company	10-11-2001			ĺ
/RI/		wo	01/74835		Bristol-Myers Squibb Company	10-11-2001			l
j.		WO	01/03451		Asahi Kasel Kabushiki Kalsha	11-00-2001	No trans.	Lai	ic
7KI/		wo	01/85695		Bristol-Myers Squibb Co.	11-15-2001			
7R1/		wo	01/91752		Merck & Co., Inc.	12-06-2001			l

Examiner	(D 1 1 (0.4/0.0/0.07)	Date	
Signature	/Roy Issac/ (04/30/2007)	Considered	. 04/30/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸ Applicant is to place a check mark here if English language Translation is attached.



Please type a p	olus sign (+)	inside this	box →	П
-----------------	---------------	-------------	-------	---

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	ite for form 1449A/	PTO			Complete if Known			
					Application Number	10/734,573		
INF	ORMATIO)N D	ISCL	OSURE	Filing Date	12-12-2003		
STATEMENT BY APPLICANT					First Named Inventor	FRICK, et al.		
					Group Art Unit	Not Yet Known		
(use as many sheets as necessary)					Examiner Name	Not Yet Known		
Sheet	3	o		5	Attorney Docket Number	DEAV2002/0087 - US - NP		


				U.S. PATENT DOC	JMENTS			
	a:	U.S. Paten	t Document	Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines,		
Examiner Initials*	Cite No.1	Number	Kind Code ² (if known)	of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear		
		•						
								
	Ī							
	1							
ì								
		· ·						
				· · · · · · · · · · · · · · · · · · ·				
						· · · · · · · · · · · · · · · · · · ·		
			· · · · · ·		1			

				FOR	EIGN PATENT DOCUMENT	S		
Examiner	eminer Cite Foreign Patent Docum		r Cite	cument Kind Code ⁵	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant	
Initials	No.1	Office	3 Number4	(if known)	Applicant of Cited Document	MM-DD-YYYY	Passages or Relevant Figures Appear	T6
		wo	02/068439		Kissei Pharmaceuticai Co., Ltd	09-06-2002	No transla	tiþi
(5)		we	02/080440		Kissel Pharmaceuticals Co., Lt	09-08-2002	No transl	atl
/KI/		wo	02/080935		Ortho McNeil Pharmaceutical I	10-17-2002		\neg
<u> </u>		wo	02/080936		Ortho McNeil Pharmaceutical I	10-17-2002		
		WO	02/2887Z		Rissel Pharmaceutical Co., Ltd	04-11-2002	—No transl	atti
		WO	02/30002		Ajinomoto Oo., Inc.	05 10 2002	No trans	
		wo	02/44132		Kissel Pharmaceutical Co., Ltd	08-06-2002	—— No tran	
		WO	03/020209		CLOMBIK	03 13 2003	No tran	314
/RI/]		wo	97/26265		Novo Nordisk A/S	07-24-1997		
/RI/I		wo	97/41097		Dr. Reddy's Research Foundat	11-06-1997		

Examiner		Date	04/30/2007
Signature	/Roy Issac/ (04/30/2007)	Considered	04/30/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.





Please type a plus sign (+) inside this box	→□	
---	----	--

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Dilection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitut	te for form 1449A/PT(5		Complete if Known			
				Application Number	10/734,573		
INFORMATION DISCLOSURE				Filing Date	12-12-2003		
STA	TEMENT B	YA	IPPLICANT	First Named Inventor	FRICK, et al.		
				Group Art Unit	Not Yet Known		
(use as many sheets as necessary)				Examiner Name	Not Yet Known		
Sheet	4	of	5	Attorney Docket Number	DEAV2002/0087 - US - NP		

	U.S. PATENT DOCUMENTS								
Examiner Initials	Cite No. ¹	U.S. Paten Number	Kind Code ²	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
L									
 									
									
									
\vdash									
					 				
									
			- 						
\vdash									
						-			
				···-··································					
				····	1				
		,		·····					

				FOR	EIGN PATENT DOCUMEN	rs		
Examiner Initials*	Cite No.1	Office	Foreign Patent Doc 3 Number	Kind Code ⁵ (il known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ ^β
/RIA		wo	98/08871		Novo Nordisk A/S	03-05-1998		I^-
/RI/		wo	99/03861		Novo Nordisk A/S	01-28-1999		
/RI/_		wo	99/15525		Sanofi	04-01-1999		
								₩
						 		+
								\perp
			<u> </u>			ļ		┼
1 1		l				1		

Examiner Signature	/Roy Issac/ (04/30/2007)	Date Considered	04/30/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Please type a	plus sign ((+) inside this	box →
riease type a	pius sign i	(*) 1113108 0113	

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitu	te for form 1449B/	PTO	•	Complete if Known		
				Application Number	10/734,573	
INFO	ORMATIC	ON D	ISCLOSURE	Filing Date	12-12-2003	
STATEMENT BY APPLICANT				First Named Inventor	FRICK, et al.	
				Group Art Unit	Not Yet Known	
	(use as man	y sheet	s as necessary)	Examiner Name	Not Yet Known	
Sheet	5	of	5	Attorney Docket Number	DEAV2002/0087 - US - NP	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
/RI/		ASAKAWA A. et al., Cocaine-Amphetamine-Regulated Transcript Influences Energy Metabolism, Anxiety and Gastric Emptying in Mice, Hormone Metabolism Research, (2001), Vol. 33, pp. 554 - 558	
/RI/		LEE Daniel W. et al., Leptin agonists as a potential approach to the treatment of obesity, Drugs of the Future, (2001), Vol. 26, No. 9, pp. 873 - 881	
/RI/		OKADA Hiroshi et al., Synthesis and Antitumor Activities of Prodrugs of Benzoylphenylureas, Chemical Pharmaceutical Bulletin, (1994), Vol. 32, No. 1, pp. 57 - 61	
/RI/		SALVADOR Javier et al., Perspectives In The Therapeutic Use Of Leptin, Expert Opinion Pharmacotherapy, (2001), Vol. 2, No. 10, pp. 1615 - 1622	
/RI/		TYLE Praveen, Iontophoretic Devices for Drug Delivery, Pharmaceutical Research, (1986), Vol. 3, No. 6, pp. 318 - 326	
/RI/		ZUNFIT H. J. F. et al., Carob Pulp Preparation for Treatment of Hypercholesterolemia, Advances In Therapy, (2001), Vol. 18, No. 5, pp. 230 - 236	

Examiner	/Roy Issac/ (04/30/2007)	Date	04/00/0007
Signature	11(0) 133ac/ (04/30/2007)	Considered	04/30/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English tanguage Translation is attached.





Please type a plus sign (+) inside this box 🛶	굣
---	---

Sheet

PJease type a plus sign (+) inside this box

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

bstitute for form 1449B/PTO NFORMATION DISCLOSURE

Complete if Known **Application Number** 10/734,573 Filing Date 12-12-2003 **First Named Inventor** FRICK, et. al. Group Art Unit 1615 **Examiner Name** Not Yet Assigned Attorney Docket Number DEAV2002/0087 - US - NP

(use as many sheets as necessary) of

1

STATEMENT BY APPLICANT

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), T2 Initials' No.1 publisher, city and/or country where published. /RI/ DIEZ-SAMPEDRO, A., et. al., Residue 457 Controls Sugar Binding and Transport in the Na+/Glucose Cotransporter, The Journal of Biological Chemistry Vol.276, No. 52, Issue of December 28, pp. 49188-49194, (2001)

Examiner	/Roy Issac/ (04/30/2007)	Date	0.4/0.0/0.007
Signature	, (Considered	04/30/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

